SDGRSchrödinger, Inc.
$27.27+40% 1Y
$27.27
$11.0752 weeks$32.59
The financials
Schrödinger, Inc. by the numbers
Schrödinger, Inc. (SDGR) reported revenue of $59M in Q2 2026 (quarter ended Jun 30, 2026), up 7.5% from the same quarter a year earlier. That came with a gross margin of 55% and net income of $6.0M (10% of revenue). For the full year FY2025, revenue was $256M (+23% year on year) and net income −$103M. Its largest product in Q2 2026 was Drug Discovery at $23M, 40% of the disclosed total, ahead of Hosted Software at 26%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $59M | $55M | +7.5% |
| Gross profit | $32M | $26M | +24% |
| Operating income | −$42M | −$53M | n/a |
| Net income | $6.0M | −$43M | to a profit |
| Diluted EPS | $0.08 | −$0.59 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Drug Discovery | $23M | 40% |
| Hosted Software | $15M | 26% |
| Drug Discovery Services | $8.8M | 15% |
| Contribution | $3.4M | 5.9% |
| Professional Services | $3.2M | 5.6% |
| Software Contribution | $2.9M | 5.1% |
| Oncology Neurology And Immunology Product | $500K | 0.9% |
| Drug Discovery Contribution | $438K | 0.8% |
| Software Products And Services | $3K | 0.0% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $57.4M (+14%)
Drug Discovery grew +65% year on yearSoftware Products And Services -73% year on year
Segment Latestquarter on quarteryear on year
- Drug Discovery$23.0M$23.0Mquarter on quarter +0.47%year on year +65%+0.47%+65%
- Hosted Software$15.2M$15.2Mquarter on quarter +25%year on year +36%+25%+36%
- Drug Discovery Services$8.8M$8.8Mquarter on quarter -25%year on year +16%-25%+16%
- Contribution$3.4M$3.4Mquarter on quarter +4565%year on year -29%+4565%-29%
- Professional Services$3.2M$3.2Mquarter on quarter +22%year on year +35%+22%+35%
- Software Contribution$2.9M$2.9Mquarter on quarter n/ayear on year -35%n/a-35%
- Oncology Neurology And Immunology Product$500.0K$500.0Kquarter on quarter -29%year on year -29%-29%-29%
- Drug Discovery Contribution$438.0K$438.0Kquarter on quarter +196%year on year +59%+196%+59%
- Software Products And Services$3.0K$3.0Kquarter on quarter 0.00%year on year -73%0.00%-73%
On our screens:Most shorted stocks
Health Information Services
Ranks #15 of 20 by RyuScore